Drug Trial Radar · NCT01143389
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Last checked: Nov 19, 2026Latest source record: Jun 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
510
Actual
Start
May 2010
Primary completion
May 30, 2017
Study completion Aug 30, 2017
Sponsor
- Lead sponsor
- Price Vision GroupIndustry
- Sponsor type
- Industry
- First posted
- Jun 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.
Conditions
- Keratoconus
- Post-Refractive Ectasia
Interventions
RiboflavinDrug
Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX lightDevice
UVX 365 nm wavelength light source is applied with continued application of riboflavin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Maximum Keratometry From Baseline to 6 Months After TreatmentTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Price Vision Group
Indianapolis, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.